Definition of Lapatinib. Meaning of Lapatinib. Synonyms of Lapatinib

Here you will find one or more explanations in English for the word Lapatinib. Also in the bottom left of the page several parts of wikipedia pages related to the word Lapatinib and, of course, Lapatinib synonyms and on the right images related to the word Lapatinib.

Definition of Lapatinib

No result for Lapatinib. Showing similar results...

Meaning of Lapatinib from wikipedia

- Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb marketed by Novartis) is an orally active drug for breast...
- drug lapatinib was approved by the U.S. FDA to treat advanced-stage or metastatic breast cancer in combination with Roche's capecitabine. Lapatinib eliminates...
- 8 months (30.9 months vs. 25.1 months) compared to the combination of lapatinib and capecitabine. Based on that trial, the U.S. Food and Drug Administration...
- Lantidra Lantrisul Lantus (Sanofi-Aventis) lapaquistat acetate (USAN) lapatinib ditosylate (USAN) lapirium chloride (INN) laprafylline (INN) la****ucel-T...
- vulnerability to oxytosis/ferroptosis via a combination of siramesine and lapatinib. These cells also exhibited an autophagic cycle independent of ferroptotic...
- while attempting to determine the toxicity and effectiveness of the drug. Lapatinib, FDA-approved for treatment in conjunction with chemotherapy or hormone...
- this setting. Sorafenib (Nexavar) Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bosutinib (Bosulif) Ponatinib (Iclusig) Asciminib...
- inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
- inhibitors: Agerafenib Altiratinib Axitinib Cabozantinib Cediranib Fruquintinib Lapatinib Lenvatinib Motesanib Nintedanib Pazopanib Pegaptanib Rebastinib Regorafenib...
- to develop new therapeutic strategies. HER2 kinase inhibitors, such as lapatinib, have also demonstrated clinical efficacy in HER2 overexpressing breast...